Core Viewpoint - Investors in Theravance Biopharma, Inc. (TBPH) should closely monitor the stock due to significant movements in the options market, particularly the March 20, 2026 $10 Put option which has high implied volatility [1] Group 1: Implied Volatility - Implied volatility indicates the market's expectation of future stock movement, with high levels suggesting anticipation of a significant price change or an upcoming event that could trigger a rally or sell-off [2] - Options traders often seek high implied volatility options to sell premium, aiming to benefit from the decay of the option's value if the stock does not move as expected [4] Group 2: Analyst Sentiment - Theravance Biopharma currently holds a Zacks Rank 3 (Hold) within the Medical – Drugs industry, which is in the top 39% of the Zacks Industry Rank [3] - Over the past 60 days, no analysts have increased earnings estimates for the current quarter, while one has decreased them, resulting in a drop in the Zacks Consensus Estimate from 46 cents per share to 44 cents [3]

Core Insights - Zacks Premium provides various tools to enhance stock market investment confidence and knowledge [1] - The Zacks Style Scores are complementary indicators that help investors select stocks likely to outperform the market in the short term [3] Zacks Style Scores Overview - The Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each assessing different investment characteristics [4][5][6][7] - Value Score focuses on identifying undervalued stocks using financial ratios [4] - Growth Score evaluates stocks based on their future earnings and financial health [5] - Momentum Score identifies trends in stock prices and earnings outlooks to guide investment timing [6] - VGM Score combines all three Style Scores to highlight stocks with the best overall potential [7] Zacks Rank and Style Scores Interaction - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify stock selection [8] - Stocks rated 1 (Strong Buy) have historically outperformed the S&P 500, with an average annual return of +23.9% since 1988 [9] - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [10] - Stocks with lower ranks, even with good Style Scores, may still face downward price pressure due to negative earnings outlooks [11] Company Spotlight: Theravance Biopharma (TBPH) - Theravance Biopharma is a biopharmaceutical company focused on respiratory medicines, formed from a split in 2014 [12] - TBPH currently holds a Zacks Rank of 3 (Hold) and has a VGM Score of A [12] - The company has a Momentum Style Score of B, with shares increasing by 10.7% over the past four weeks [13] - Recent upward revisions in earnings estimates indicate a positive outlook, with the Zacks Consensus Estimate rising by $0.01 to $0.24 per share [13] - TBPH has an average earnings surprise of +55.4%, making it a notable candidate for investors [13]

Regulatory Developments - Atossa Therapeutics, Inc. (ATOS) received Orphan Drug Designation from the U.S. FDA for (Z)-endoxifen to treat Duchenne muscular dystrophy, leading to a 12.98% increase in stock price to $0.69 [1] - ImmunityBio, Inc. (IBRX) reported that enrollment in its QUILT-2.005 trial for bladder cancer exceeded expectations, with over 85% enrollment, anticipating full enrollment by Q2 2026 and FDA submission by year-end 2026, resulting in a 9.43% stock price increase to $6.04 [2] Financing Updates - Foghorn Therapeutics Inc. (FHTX) closed a $50 million registered direct financing at a 30% premium, contributing to a 4.02% increase in stock price to $6.26 [4] - Femasys Inc. (FEMY) received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, allowing until July 13, 2026, for compliance, leading to a 10.68% increase in stock price to $0.72 [3] Investor Sentiment - Theravance Biopharma, Inc. (TBPH) saw a 5.00% increase in stock price to $21.01 despite no new announcements [5] - Daré Bioscience, Inc. (DARE) experienced a modest gain of 1.04% to $1.95 without any new news [4]

Market Overview - U.S. stock futures showed mixed results, with Dow futures declining by 0.2% [1] Company-Specific Movements - Jefferson Capital Inc (NASDAQ:JCAP) experienced a significant drop of 4.4%, trading at $22.00, following the announcement of a secondary offering of 10 million shares [1] - MOBIX LABS, INC. (NASDAQ:MOBX) fell sharply by 25.4% to $0.24 due to plans for a common stock offering [2] - Datavault AI Inc (NASDAQ:DVLT) shares decreased by 12.4% to $1.26 after a previous surge of 43% on Monday, linked to a nationwide deployment announcement [2] - BitVentures Ltd – ADR (NASDAQ:BVC) saw a decline of 9.7% to $13.33 after a 5% gain on Monday [2] - Zenas Biopharma Inc (NASDAQ:ZBIO) tumbled by 6.6% to $15.50 following a 52% drop on Monday due to Phase 3 trial results [2] - Theravance Biopharma Inc (NASDAQ:TBPH) dipped 6% to $17.07 after a 3% decline on Friday [2] - Graphic Packaging Holding Co (NYSE:GPK) fell 4.9% to $14.70 ahead of its fourth quarter financial results announcement [2] - ATRenew Inc (NYSE:RERE) declined by 4.1% to $5.65 after a 9% gain on Monday [2] - Rezolve AI PLC (NASDAQ:RZLV) fell 3.7% to $3.07 in pre-market trading [2] - NovaBay Pharmaceuticals Inc (NYSE:NBY) slipped 3.4% to $6.52 after a 15% jump on Monday [2] - Starfighters Space Inc (NYSE:FJET) decreased by 3.3% to $9.08 after a 10% dip on Monday [2]

Market Overview - U.S. stock futures showed positive movement, with Nasdaq 100 futures increasing by over 150 points on Monday [1] Company-Specific Movements - mF International Limited (NASDAQ:MFI) experienced a significant decline, falling 4.6% to $17.61 in pre-market trading after filing for a mixed shelf [1] - SBC Medical Group Holdings Inc (NASDAQ:SBC) dropped 18.9% to $3.51 in pre-market trading [2] - Aimei Health Technology Co Ltd (NASDAQ:AFJK) decreased by 7.7% to $70.00 in pre-market trading [2] - Theravance Biopharma Inc (NASDAQ:TBPH) fell 6% to $17.07 in pre-market trading, following a 3% decline on Friday [2] - Comcast Corp (NASDAQ:CMCSA) tumbled 4.6% to $28.18 in pre-market trading [2] - Equinor ASA (NYSE:EQNR) decreased by 3.6% to $23.66 in pre-market trading after a 4% gain on Friday [2] - Canadian Natural Resources Ltd (NYSE:CNQ) fell 3.4% to $33.15 in pre-market trading [2] - Xpeng Inc – ADR (NYSE:XPEV) slipped 3.3% to $19.75 in pre-market trading [2] - Two Harbors Investment Corp (NYSE:TWO) declined 3.2% to $10.24 in pre-market trading [2] - NetEase Inc (NASDAQ:NTES) fell 2.9% to $143.29 in pre-market trading, following the announcement of Yingfeng Ding's retirement from his position as executive vice president and head of the Interactive Entertainment Group [2]

Core Insights - Zacks Premium offers various tools to enhance stock market investment confidence and knowledge [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the next 30 days [3][4] - Each stock is rated from A to F, with A indicating the highest potential for outperformance [4] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios like P/E, PEG, and Price/Sales [4] Growth Score - The Growth Style Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [5] Momentum Score - The Momentum Style Score assesses stocks based on price trends and earnings outlook changes, helping investors capitalize on upward or downward price movements [6] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [7] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.81% since 1988, significantly outperforming the S&P 500 [8][9] - There are over 800 top-rated stocks available, making it essential to use Style Scores to narrow down choices [9] Stock to Watch: Theravance Biopharma (TBPH) - Theravance Biopharma is a biopharmaceutical company focused on respiratory medicines, rated 2 (Buy) on the Zacks Rank with a VGM Score of A [12] - The company is particularly appealing to growth investors, with a Growth Style Score of A and a forecasted year-over-year earnings growth of 175% for the current fiscal year [13] - Recent upward revisions in earnings estimates and a strong average earnings surprise of +55.4% further enhance TBPH's investment appeal [13]

Core Viewpoint - Theravance Biopharma (TBPH) shares have increased by 1.7% over the past four weeks, closing at $18.79, with a mean price target of $26.71 indicating a potential upside of 42.2% according to Wall Street analysts [1] Price Targets - The average price target consists of seven estimates ranging from a low of $13.00 to a high of $42.00, with a standard deviation of $11.1, indicating variability among analysts [2] - The lowest estimate suggests a decline of 30.8% from the current price, while the highest estimate indicates a potential upside of 123.5% [2] Analyst Sentiment - Analysts are optimistic about TBPH's earnings prospects, as indicated by a trend of upward revisions in earnings estimates, which historically correlates with stock price movements [4][11] - Over the past 30 days, one earnings estimate has increased, leading to a 6.7% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank - TBPH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of TBPH's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Core Viewpoint - Theravance Biopharma is focusing on ampreloxetine, an orphan drug aimed at treating neurogenic orthostatic hypotension in patients with multiple system atrophy, with pivotal Phase III study data expected in Q1 2026 [2][3]. Group 1: Product Overview - Ampreloxetine is designed to address a significant unmet need in symptomatic neurogenic orthostatic hypotension (nOH) [3]. - The drug is positioned as a once-daily oral medication that offers a durable treatment effect, potentially transforming the treatment landscape for affected patients [3]. Group 2: Clinical Development - The pivotal Phase III study, named CYPRESS, is nearing completion, with results anticipated in the first quarter of 2026 [2].

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Theravance Biopharma (TBPH) - Theravance Biopharma currently holds a Momentum Style Score of A, indicating strong momentum characteristics [3] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook based on historical performance metrics [4] Performance Metrics - TBPH shares have increased by 9.85% over the past week, outperforming the Zacks Medical - Drugs industry, which rose by 4.47% during the same period [6] - Over the past month, TBPH's price change is 25.76%, significantly higher than the industry's 0.88% [6] - In the last quarter, TBPH shares rose by 29.72%, and over the past year, they have gained 87.75%, while the S&P 500 increased by only 6.25% and 14.29%, respectively [7] Trading Volume - TBPH's average 20-day trading volume is 594,234 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the last two months, 2 earnings estimates for TBPH have been revised upwards, while only 1 estimate was revised downwards, leading to an increase in the consensus estimate from -$0.06 to $0.24 [10] - For the next fiscal year, 3 estimates have moved upwards with no downward revisions, indicating positive sentiment regarding future earnings [10] Conclusion - Given the strong momentum indicators and positive earnings outlook, TBPH is positioned as a promising investment opportunity with a Momentum Score of A and a Zacks Rank of 2 (Buy) [12]